LONDON, UK / ACCESSWIRE / September 30, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2020.
All financial amounts are stated in GBP British pounds unless otherwise indicated.
Key highlights
CAR-T cells
CDX bi-specific antibodies
COVID-19 Project
Autoimmune diseases
Human Postnatal Hemogenic Endothelial Cell (“Hu-PHEC”) cell therapy
Funding
Fuller details on these developments are contained in the Interim Management Report below.
Commenting on the Outlook for Hemogenyx Pharmaceuticals, Sir Marc Feldmann, Chairman, said:
“The Board is very pleased with the progress being made with the development of CDX bi-specific antibodies and the development of CAR-T technology for the treatment of leukaemia, as well as the potential value that can be created through the Company’s updated humanised mouse model. The Company’s efforts to combat the COVID-19 global pandemic and other viral pathogens are of special importance. The Board believes that the Company is well advanced on the planned development steps for its CDX antibodies, and will provide further updates to shareholders as we progress toward the completion of our collaboration with GlobalCo and enter pre-clinical development. In all, the Company is on track to achieve the inflection point in its development to which I referred in the 2019 annual report.”
Click on or paste the following URL into your web browser to view announcement in full:
http://www.rns-pdf.londonstockexchange.com/rns/5155A_1-2020-9-29.pdf
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/608393/Hemogenyx-Pharmaceuticals-PLC-Announces-Interim-Results-for-the-Period-Ended-30-June-2020
MARIETTA, Ohio, March 18, 2025 /PRNewswire/ -- Caron Scientific, Inc., a leading provider of advanced…
The DDC Group unifies all "DDC" operations and brands to drive exceptional business outcomes across…
Next-gen smart mirror integrates AI-powered health monitoring with seamless 4G connectivity for enhanced telehealth, retail,…
Open-source tools will help developers generate evidence that meets the needs of all decision-makers through…
BEIJING, March 18, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"),…
The Talkdesk Ascend AI platform, through agentic artificial intelligence, gives companies access to advanced multi-channel…